Moderna's Financial Forecast Update: Navigating Post-Pandemic Headwinds

Moderna reduced its 2025 revenue forecast due to deferred UK vaccine deliveries. Despite a smaller-than-expected quarterly loss, its shares fell 7%. The company faces challenges from declining COVID-19 vaccine demand, regulatory delays, and cost pressures while seeking growth through new mRNA products.

Moderna has adjusted its revenue forecast for 2025 following the deferment of some COVID-19 vaccine deliveries to the UK. This has overshadowed the company's smaller-than-expected second-quarter loss and resulted in a 7% drop in its share value.

The revised revenue projection of $1.5 billion to $2.2 billion highlights the challenges the vaccine maker faces, including reduced demand for COVID-19 shots, a slower RSV rollout, and regulatory delays. The company is working to cut costs and regain growth momentum after pandemic-era profits have waned.

Finance Chief James Mock stated that 40% to 50% of this year's revenue is expected in the third quarter, citing a shift due to the UK's fiscal policies. Meanwhile, Moderna plans to focus on its new mRNA products and aims for further cost reductions in 2025, maintaining its strategic goals amidst these challenges.

(With inputs from agencies.)